Ready-to-use Biosimilar Cell Lines
UGA Biopharma GmbH offers to their clients so called Ready-to-use Biosimilar Cell Lines. This are in-house developed CHO cell lines stably expressing different biosimilar molecules, that are instantly available for in-licensing. The client profits, because the cell lines are directly available, and development data including titer and quality attributes are promptly accessible.
Dossiers, shortly summarizing the development and the associated available quality and titer data of each Ready-to-use Biosimilar Cell Line are available for all cell lines listed below.
Ready-to-use Biosimilar Cell Lines including lab scale USP and DSP
Full package ready for sales now:
Research Cell Bank (RCB) including safety testing
Optimized fermentation process (USP)
Optimized downstream purification process (DSP) and analytics
Including proof of activity of the expressed protein
Remarkable Bevacizumab clone stability for at least 10 weeks of cultivation.
Under Development
Those cell lines are currently under development at UGA Biopharma.
Former Projects
Those cell lines were developed by UGA but are currently not available as Ready-to-use Biosimilar Cell Lines.
UGA has already gained a lot of experience with the molecules listed below. Furthermore, the costs to develop those projects for the client are reduced, because several methods, like e.g. DSP or analytical methods, were already established in-house.
These biosimilar expressing cell lines are perfect for clients that want to profit from our long-standing experience. The client can get a cell line with a reliable high titer from 4 to 7 g/L (for easy to express mAb) in a very short development timeline. Even lower development costs are guaranteed.
Aflibercept is a recombinant fusion protein with complex
post-translational modifications. Therefore deep understanding of biosimilar
development is required to develop a biosimilar like Aflibercept.
Biosimilary of Darbepoetin alfa expressing cell line could be improved. Please consider the isolectical focusing (IEF) gel of Darbepoetin alfa biosimilars and the originator.
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
If you have any further
question about the licensing conditions of the cell line, please do
not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell
lines are only available for experimental use relating to the subject-matter of
the patented invention or for studies and trials necessary to obtain a
marketing authorization for medicinal products in accordance with Art. 11 No. 2
and 2b of the German Patent Act, but not in any larger quantities, nor for any
other purposes.
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
If you have any further question about the licensing conditions of the cell line, please do not hesitate to contact us via: info@ugabiopharma.com
Disclaimer: Biosimilar cell lines are only available for experimental use relating to the subject-matter of the patented invention or for studies and trials necessary to obtain a marketing authorization for medicinal products in accordance with Art. 11 No. 2 and 2b of the German Patent Act, but not in any larger quantities, nor for any other purposes.
New Cell line development
Moreover, UGA wants to highlight that all cell lines listed above, can also be developed as NEW cell lines.
If you are interested in a molecule or biosimilar that is not listed here, please also contact us under info@ugabiopharma.com and we will discuss your upcoming project with you. We will be glad to provide you with an individual project proposal and attractive quotation.
UGA has experience with all major protein classes: monoclonal antibodies (mAbs, IgG1 and IgG4), bispecific antibodies, chimeric antibodies, humanized antibodies, fusion proteins, enzymes, hormones, and EPO derivates.
Disclaimer
Back to products and services
Contact
UGA Biopharma GmbHNeuendorfstraße 20a
16761 Hennigsdorf
Germany
E-mail: info@ugabiopharma.com
Phone: +49(0)3302 / 2024900